Sanofi-Aventis China R&D Head Frank Jiang On Fast And Furious Adaptation In China: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis is grabbing a larger share of the emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down with PharmAsia News to discuss the environment in China and how Sanofi is approaching R&D there. Jiang is also a member of the networking organization BayHelix, which links Chinese life sciences executives.
You may also be interested in...
Sanofi-Aventis China R&D Head Frank Jiang On Fast And Furious Adaptation In China: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis is grabbing a larger share of emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down with PharmAsia News to discuss the environment in China and how Sanofi is approaching R&D there. Jiang is also a member of the networking organization BayHelix, which links Chinese life sciences executives.
Sanofi-Aventis China R&D Head Frank Jiang On Fast And Furious Adaptation In China: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis is grabbing a larger share of emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down with PharmAsia News to discuss the environment in China and how Sanofi is approaching R&D there. Jiang is also a member of the networking organization BayHelix, which links Chinese life sciences executives.
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7